ATE241380T1 - Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren - Google Patents

Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren

Info

Publication number
ATE241380T1
ATE241380T1 AT00916545T AT00916545T ATE241380T1 AT E241380 T1 ATE241380 T1 AT E241380T1 AT 00916545 T AT00916545 T AT 00916545T AT 00916545 T AT00916545 T AT 00916545T AT E241380 T1 ATE241380 T1 AT E241380T1
Authority
AT
Austria
Prior art keywords
vascular permeability
modulation
tie2 receptor
receptor activators
mammal
Prior art date
Application number
AT00916545T
Other languages
English (en)
Inventor
Chitra Suri
George D Yancopoulos
Gavin Thurston
Donald Mcdonald
Original Assignee
Regeneron Pharma
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/286,033 external-priority patent/US6455035B1/en
Application filed by Regeneron Pharma, Univ California filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE241380T1 publication Critical patent/ATE241380T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT00916545T 1999-03-26 2000-03-20 Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren ATE241380T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12653999P 1999-03-26 1999-03-26
US09/286,033 US6455035B1 (en) 1999-03-26 1999-04-05 Angiopoietins and methods of use thereof
PCT/US2000/007336 WO2000057901A1 (en) 1999-03-26 2000-03-20 Modulation of vascular permeability by means of tie2 receptor activators

Publications (1)

Publication Number Publication Date
ATE241380T1 true ATE241380T1 (de) 2003-06-15

Family

ID=26824785

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00916545T ATE241380T1 (de) 1999-03-26 2000-03-20 Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren

Country Status (14)

Country Link
EP (1) EP1165115B1 (de)
JP (1) JP2002540165A (de)
AT (1) ATE241380T1 (de)
AU (1) AU769198B2 (de)
CA (1) CA2368670C (de)
DE (1) DE60003011T2 (de)
DK (1) DK1165115T3 (de)
ES (1) ES2199804T3 (de)
HK (1) HK1043537A1 (de)
IL (2) IL145504A0 (de)
NO (1) NO329198B1 (de)
NZ (1) NZ514434A (de)
PT (1) PT1165115E (de)
WO (1) WO2000057901A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022176A1 (en) 2000-09-15 2002-03-21 Genvec, Inc. Method of modulating neovascularization
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
AU2006228095B2 (en) * 2001-10-11 2010-11-04 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
EA011866B1 (ru) * 2004-10-19 2009-06-30 Амджен Инк. Агенты, специфически связывающие ангиопоэтин-2
WO2006068953A2 (en) 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
EP1962903B1 (de) * 2005-12-15 2013-03-13 MedImmune Limited Kombination eines angiopoetin-2-antagonisten und eines vegf-a, kdr- und/oder fltl-antagonisten zur behandlung von krebs
EP3252079B8 (de) 2006-04-07 2020-09-09 Aerpio Therapeutics LLC An die humane proteintyrosinphosphatase-beta (hptp-beta) bindende antikörper und anwendungen davon
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
RU2509085C2 (ru) 2008-01-28 2014-03-10 Медиммун Лимитед Стабилизированные антитела против ангиопоэтина-2 и их применение
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CN108635350A (zh) * 2009-01-12 2018-10-12 爱尔皮奥治疗有限公司 治疗血管渗漏综合征的方法
AU2016203254B2 (en) * 2009-01-12 2018-09-13 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome
SG10201505672TA (en) 2009-07-06 2015-09-29 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
CA2850824C (en) 2011-10-13 2023-01-03 Aerpio Therapeutics, Inc. Treatment of ocular disease
ES2928162T3 (es) 2013-03-15 2022-11-15 Eyepoint Pharmaceuticals Inc Composiciones, formulaciones y métodos para tratar enfermedades oculares
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US9902767B2 (en) 2013-07-29 2018-02-27 Samsung Electronics Co., Ltd. Method of blocking vascular leakage using an anti-ANG2 antibody
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
EP3116503A4 (de) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta-hemmer
EP3352856B1 (de) 2015-09-23 2021-08-18 Aerpio Pharmaceuticals, Inc. Aktivatoren von tie-2 zur verwendung bei der behandlung des augeninnendrucks
WO2018017714A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
US11253502B2 (en) 2019-04-29 2022-02-22 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the Schlemm's canal

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6277318A (ja) * 1985-10-01 1987-04-09 Eisai Co Ltd 熱傷治療剤
US5482930A (en) * 1993-06-09 1996-01-09 The Regents Of The University Of California Anti-inflammatory composition and method with des-Tyr dynorphin and analogues
CA2263890C (en) * 1996-08-23 2013-05-14 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
US6365154B1 (en) * 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies

Also Published As

Publication number Publication date
DK1165115T3 (da) 2003-09-22
HK1043537A1 (zh) 2002-09-20
WO2000057901A1 (en) 2000-10-05
EP1165115A1 (de) 2002-01-02
NO20014673D0 (no) 2001-09-26
NZ514434A (en) 2003-11-28
AU3763400A (en) 2000-10-16
EP1165115B1 (de) 2003-05-28
DE60003011D1 (de) 2003-07-03
IL145504A0 (en) 2002-06-30
PT1165115E (pt) 2003-10-31
NO20014673L (no) 2001-11-22
CA2368670A1 (en) 2000-10-05
JP2002540165A (ja) 2002-11-26
AU769198B2 (en) 2004-01-22
NO329198B1 (no) 2010-09-13
IL145504A (en) 2008-08-07
ES2199804T3 (es) 2004-03-01
CA2368670C (en) 2012-06-05
DE60003011T2 (de) 2004-04-08

Similar Documents

Publication Publication Date Title
ATE241380T1 (de) Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren
DE60010098D1 (de) 28-epirapaloge
TR200002480T2 (tr) İzaşemi tedavisi için guanidin türevleri
PT991619E (pt) Inibidores da adesao celular mediada pela alfa4beta1
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
DE60008133D1 (de) Farbstoff-markierte imidazochinolinverbindungen
DE60043229D1 (de) Zusammensetzung zur gefässbeschichtung
DK1083903T3 (da) Brobundne indenopyrrolocarbazoler
ATE382060T1 (de) Moleküle und verfahren zur inhibierung der freisetzung von kim-1
GB0011358D0 (en) Novel use
ATE260675T1 (de) Methoden zur behandlung der salzabhängigen hypertonie
DK1411916T3 (da) Fremgangsmåder og materialer til behandling af testosteronmangel hos mænd
DE60137835D1 (de) Modifizierte zytokine für krebs therapie
DK1178726T3 (da) Vandig opløsning til konservering af væv og organer
MY121523A (en) Resorcinol derivatives
EA199901043A1 (ru) ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
BR0114884A (pt) Compostos calcilìticos
NZ331678A (en) Method of checking integrity of modified atmosphere package by placing gas indicator between package and liner
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung
DE69732784D1 (de) Inhibierung von invasiver remodulierung
FI991365L (fi) Valkaisuaktivaattori ja menetelmä aktivaattorin käyttämiseksi
DE60233819D1 (de) Doppelester
SE0003236D0 (sv) Procedure for treatment of autism by inhibition of post-proline-cleaving enzymes
DE50009728D1 (de) Mopwaschmittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1165115

Country of ref document: EP